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Introduction: COPD is an inflammatory disease with major co-morbidities. It has recently been suggested that
depression may be the result of systemic inflammation. We aimed to explore the association between systemic
inflammation and symptoms of depression and fatigue in patients with mainly moderate and clinically stable
COPD using a range of inflammatory biomarkers, 2 depression and 2 fatigue scales.
Method: We assessed 120 patients with moderate COPD (FEV1% 52, men 62%, age 66). Depression was assessed
using the BASDEC and CES-D scales. Fatigue was assessed using the Manchester COPD-fatigue scale (MCFS) and
the Borg scale before and after 6MWT. We measured systemic TNF-a, CRP, TNF-a-R1, TNF-a-R2 and IL-6.
Results: A multivariate linear model of all biomarkers showed that TNF-a only had a positive correlation with
BASDEC depression score (p = 0.007). TNF-a remained positively correlated with depression (p = 0.024) after
further adjusting for TNF-a-R1, TNF-a-R2, 6MWD, FEV1%, and pack-years. Even after adding the MCFS score, body
mass and body composition to the model TNF-a was still associated with the BASDEC score (p = 0.044).
Furthermore, patients with higher TNF-a level (> 3 pg/ml, n = 7) had higher mean CES-D depression score than
the rest of the sample (p = 0.03). Borg fatigue score at baseline were weakly correlated with TNF-a and CRP, and
with TNF-a only after 6MWT. Patients with higher TNF-a had more fatigue after 6MWD (p = 0.054).
Conclusion: This study indicates a possible association between TNF-a and two frequent and major co-morbidities
in COPD; i.e., depression and fatigue.
Introduction
COPD is a chronic inflammatory disease with systemic
manifestations such as muscle wasting, depression and
fatigue [1]. Systemic manifestations of COPD may sig-
nificantly affect patients’ quality of life and the prognosis
of the disease [1]. It has been suggested that systemic
manifestations may be related to systemic inflammation
in COPD [2,3].
Depression is a major comorbidity in COPD; it is
associated with poor functional performance [4], signifi-
cant impairment in health status and high mortality [5].
Fatigue is one of the most prominent disabling
symptoms in COPD [6]. It is strongly associated with
depression [7], decline in daily functional activity [6],
and substantial impairment in quality of life [8].
The association between symptoms of depression and
fatigue and systemic inflammation has been examined in
depth in healthy individuals and in illnesses such as cor-
onary heart disease (CHD) [9-11]. In COPD, patients
with more systemic inflammation as well as more
depression or fatigue have been shown to be less physi-
cally active and more exercise intolerant [4,6,12].
Recently, Barnes and Celli have speculated that depres-
sion may correlate with systemic inflammation [13] and
to date no study has addressed this.
We aimed to explore the association between systemic
inflammation and symptoms of depression and fatigue
in patients with mainly moderate and clinically stable
COPD using a range of inflammatory biomarkers, two
depression scales and two fatigue scales.
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Study subjects
The subjects enrolled in this study were 120 clinically
stable patients enrolled from outpatient clinics and
advertisements. More information on the recruitment,
inclusion and exclusion criteria, and patients’ demo-
graphic data has been described previously [4]. Briefly, all
patients had COPD according to GOLD [14] and had
been clinically stable for at least 4 weeks. Patients with
exacerbations in the last 4 weeks were either rescheduled
or excluded. We excluded patients with current or recur-
rent symptomatic ischemic heart disease, congestive
heart disease, cerebrovascular disease, dementia, lung
cancer, known psychiatric illness, maintenance treatment
with systemic corticosteroids (oral, parenteral), active
tuberculosis, inflammatory bowel syndrome or insulin-
dependent diabetes mellitus. All participants gave written
informed consent to participate in the study, and the
South Manchester Research Ethics Committee had
approved the study (Reference number 05/Q1402/41).
Assessments
For assessment of depression, two instruments were
used: The Brief Assessment Schedule Depression Cards
(BASDEC) and the Centre for Epidemiological Study on
Depression (CES-D) Scale [15,16]. Both of the scales have
been frequently used in assessing depression in COPD
[17-19]. The impact of fatigue was assessed using our
Manchester COPD fatigue scale (MCFS) which has a
high level of validity and reliability [7]. It measures total
fatigue as well as dimensional assessment of physical,
cognitive and psychosocial fatigue. The total score ranges
from 0-54, the higher the score the more the fatigue. We
also assessed the intensity of fatigue before and after a
6 minute walk test (6MWT) using the Borg scale [20].
Patients rated their feeling by the selection of one option,
ranging from 0-12, with 0 meaning no fatigue and 12
meaning extreme fatigue intensity. We used the Bioelec-
trical Impedance Analysis (BIA) to measure body compo-
sition by (Bodystat Ltd, Douglas, UK). Spirometry was
done according to the ATS/ERS Standardisation Guide-
line [21] using a Jaeger MasterScreen spirometer (Jaeger
Ltd, Hoechberg, Germany). Functional performance was
measured using the 6MWT according to the ATS guide-
line [22]. Health Status was measured by the St George’s
Respiratory Questionnaire (SGRQ) [23].
Systemic biomarkers measurement
Venous blood samples were obtained before the exercise
test to measure the required biomarkers. The samples
were centrifuged and allocated in well-marked tubes
with patients’ initials, date of donation, database number
and type of sample (plasma or serum), and samples
were immediately stored at -80°C until analysis. Plasma
TNF-a and serum IL-6 was measured by high sensitivity
ELISA (Quantikine, R&D Systems Europe, Oxon, UK)
with a lower limit of detection of 0.5 pg/ml and 0.156
pg/ml respectively. Plasma CRP was measured by high
sensitivity particle-enhanced immunonephelometry
(Cardiophase; BN systems, Dade Behring, Newark, NJ,
USA).
Statistical analysis
Normal distribution was assessed by Kolmogorov-Smir-
nov goodness of fit test and non-parametric data were
natural log transformed or presented as median and
interquartile range (IQR). The univariate correlation of
biomarkers and depression and fatigue scores were
examined by Spearman correlation. The difference in
the mean of parametric variables was examined using
the analysis of variance (ANOVA). The Mann-Whitney
and Kruskal-Wallis tests were used to examine the dif-
ference in the median value of each biomarker in two
groups or quartiles of either depression or fatigue
respectively. The chi square (x
2) test was used to exam-
ine the categorical association of systemic biomarkers
and depression and fatigue. The multivariate linear and
binary regression analyses were used to examine the
association of factors with depression or fatigue. SPSS
version 15 (SPSS Inc, USA) was used.
Results
We examined 120 patients with mainly moderate COPD
(mean FEV1% 52.5 (SD 18.5)), mean age was 66 years
and women made up 38% of the sample. Patients with
GOLD stage 2 (60 (50%)) dominated the sample while
patients with GOLD stage 1, 3 and 4 represented (6
(5%), 38 (32%) and 16 (13%)), respectively. Although the
majority of the patients were ex-smokers (86 (71.7%),
there were 34 current smokers (28.3%). The current
smokers were slightly younger, half of them were
women, and they had slightly worse airway obstruction,
more fatigue, more depressive symptoms and less lean
tissue. More demographic data are shown in table 1.
The median (IQR) of BASDEC and CES-D scores were
3 (4.5) and 10 (12) respectively, and the mean (SD)
MCFS was 24.8 (12.8) and the median (IQR) Borg scale
at baseline and post-6MWT were 0.5 (2) and 2 (3.5)
respectively.
There were mild to moderate intercorrelations
between the systemic inflammatory biomarkers as
shown in table 2.
Depression and systemic inflammation
Univariate correlation analyses showed no statistically
significant association between systemic inflammatory
biomarkers and CES-D and BASDEC depression scores
except for a weak correlation between TNF-a-R 1a n d
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ference in the median of all biomarkers between symp-
tomatically depressed and not depressed.
Using the BASDEC scores as the dependent variable, a
multivariate linear regression analysis showed a positive
association between TNF-a and depression scores (Beta
= 0.26, p = 0.007) as shown in table 3 (Module 1). The
association remained unchanged after adjusting for
TNF-a-R1 and TNF-a-R2 (Beta = 0.27, p = 0.005).
TNF-a still had a positive correlation with depression
(Beta = 0.23, p = 0.024) in the multivariate model after
further adjusting for 6MWD, FEV1%, and pack/years, as
shown in table 3 (Module 2); this model explained
15.6% of the variance in depression scores where TNF-a
alone contributed with 5%. Furthermore, adding the
total Manchester COPD Fatigue Scale (MCFS) score,
BMI and FFMI to the model did not change the find-
ings; i.e., TNF-a still had a significant positive correla-
tion with BASDEC depression score (Beta = 0.17 p =
0.044).
For exploration, we selected higher cut-off points for
each systemic biomarker to categorize the sample, and
we found that the patients with higher TNF-a level (> 3
pg/ml, n = 7) had higher mean CES-D depression score
than the rest of the sample (15 vs 10.4, p = 0.03) as
shown in figure 1. For BASDEC scores the differences
were less obvious (5.4 vs 3.6, p = 0.2). We found no sta-
tistically significant differences for CRP and IL-6.
Fatigue and systemic inflammation
We found no statistically significant correlation between
total MCFS scores and any of the systemic biomarkers.
Similarly, no univariate statistically significant correla-
tion was found between systemic biomarkers and the
physical, cognitive or psychosocial dimensions of MCFS
(p > 0.05 for all correlations). Using categorical analyses,
there was no statistically significant difference in the
median of all biomarkers between the 4 fatigue quartiles.
Similarly, we found no statistically significant difference
in the median of the inflammatory biomarkers in quar-
tiles of physical and cognitive.
Borg fatigue scores at baseline had a weak positive
correlation with TNF-a and CRP (rho = 0.24, p = 0.01,
and 0.19, p = 0.05, respectively). Similarly, Borg fatigue
scores after 6MWT had a weak correlation with TNF-a
only (rho = 0.23, p = 0.01).
For further exploration, we selected higher cut-off points
and found that the mean of the total and dimensional
MCFS score of patients with higher TNF-a (> 3 pg/ml, n
= 7) was higher than the rest of the sample, but the differ-
ences did not reach statistical significance. A similar trend
was seen for the mean fatigue score in Borg scale after
Table 1 Baseline characteristics of the sample; mean








Number 120 86 (71.7%) 34 (28.3%)
Age, yrs 66 ± 6.7 67 ± 6.9 64 ± 6.6 0.03
Females (%) 46 (38%) 30 (35%) 16 (47%) 0.4*




47.8 ± 17.7 0.12
PaO2 (kPa) 9.2 ± 1.4 9.1 ± 1.1 9.3 ± 1.2 0.4
PaCO2 (kPa) 5.2 ±.58 5.1 ± 0.5 5.3 ± 0.7 0.05
MCFS 25.1
±12.5
23.9 ± 12 28 ± 13.5 0.11








18.3 ± 3.2 17.2 ± 3.6 0.09
Pack/years Median
(IQR)
40 (25.8) 38.3 (31.1) 41.9 (22.5) 0.8#
# Mann-Whitney U Test; * x
2-Test; IQR = Interquartile Range; FEV1 % = Forced
Expiratory Volume over 1 second of predicted; PaO2 = Arterial oxygen partial
pressure; kPa = kilo Pascal; PaCO2 = Arterial carbon dioxide pressure; MCFS =
Manchester COPD Fatigue Scale; CES-D = Centre for Epidemiologic Studies
Depression Scale; BMI = Body Mass Index; FFMI = Fat-Free Mass Index.
Table 2 Univariate (Spearman (rho)) correlations between
inflammatory biomarkers
TNF-a CRP TNF R1 TNF R2
TNF-a 1
CRP 0.11 1
TNF-a R1 0.368** 0.285** 1
TNF-a R2 0.282** 0.104 .548** 1
IL-6 0.114 0.449** .391** .199*
** Correlation is significant at the 0.01 level (2-tailed).
* Correlation is significant at the 0.05 level (2-tailed).
CRP = C-reactive protein; IL-6 = Interleukin-6; TNF-a = Tumor necrosis factor-
a; TNF-a R1 = Tumor necrosis factor-a receptor1; TNF-a R2 = Tumor necrosis
factor-a receptor2
Table 3 Multivariate linear regression modules for factors
associated with depression
Module 1 Module 2
Variables Beta p Variables Beta p
TNF-a 0.26 0.007 TNF-a 0.23 0.024
CRP 0.07 0.5 TNF-a-R1 -0.13 0.3
TNF-a-R1 -0.1 0.5 TNF-a-R2 -0.13 0.3
TNF-a-R2 -0.2 0.2 6MWD -0.22 0.027
IL-6 -0.2 0.1 FEV1% 0.02 0.9
Pack/years -0.02 0.9
*BASDEC depression score was the dependent variable
CRP = C-reactive protein; FEV1 = Forced Expiratory Volume over 1 Second; IL-6
= Interleukin-6; 6MWD = 6 Minute Walk Distance; TNF-a = Tumor necrosis
factor-a;T N F - a R1 = Tumor necrosis factor-a receptor1; TNF-a R2 = Tumor
necrosis factor-a receptor2.
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was not found in multivariate analyses.
Discussion
We explored the association between systemic inflam-
mation and depression and fatigue using a range of
inflammatory biomarkers, two depression scales and two
fatigue scales in a cohort of 120 patients with clinically
stable COPD. There were modest correlations between
systemic inflammation and depression and fatigue. How-
ever, the association between TNF-a and depression
remained significant even after adjusting for confound-
ing factors in multivariate analyses. This finding was
also consistently seen in further categorical analyses.
An association between systemic inflammation and
depression could be the result of the effect of confoun-
ders. It has been suggested that both systemic
inflammation and depression correlate with poor
functional performance [4,24], fatigue [10,25], BMI
[24,26] and FFMI [4,27]. To explore the possibility of
confounding as a result of these factors, we did different
multivariate analyses. In a model with depression as the
dependent variable, adjusting for the MCFS score,
6MWD, FEV1% ,B M Ia n dF F M Id i dn o tm a r k e d l y
change the association between TNF-a and depression
and it remained statistically significant. The robustness
of this association may reflect a true association as a
result of the fact that COPD is principally a progressive
inflammatory disabling disease [1] and that major
depression or sub-threshold depressive symptoms are
quite prevalent [17,28] even in patients with moderate
clinically stable COPD [4]. Therefore, it seems plausible
that systemic inflammation is correlated with depression
as suggested by Barns and Celli [13].
Patients categories according to plasma TNF-α level






























Figure 1 M e a nC E S - Dd e p r e s s i o ns c o r e si nr e l a t i o nt op l a s m aT N F - a level. CES-D = Centre for Epidemiologic Studies Depression Scale,
TNF-a = Tumor necrosis factor-a
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bidirectional nature [29] particularly in COPD. In fact,
studies have shown that inflammatory cytokines had a
direct effect on the central nervous system including the
enhancement of negative moods [29-32]. On the other
hand, depression was associated with increased plasma
cytokines, and the production of pro-inflammatory cyto-
kines was frequently seen in depression [29,30]. This
could be clinically important given the chronic inflam-
matory progressive pattern of COPD, and opens the
possibility of effective antidepressants having an effect
on the inflammatory response system [31,33] or effective
anti-inflammatory therapy having an effect on depres-
sion, a major comorbidity in COPD.
We used our validated Manchester COPD-fatigue
scale (MCFS) [7] to assess the association between sys-
temic inflammation and fatigue and we found that
patients with less fatigue had a tendency to have lower
levels of TNF-a. We found this for both the total and
dimensional fatigue using the MCFS. Moreover, there
was a weak association between the severity (intensity)
of fatigue before and after exercise test with TNF-a and
CRP but not with TNF-a-Rs and IL-6. It has previously
been reported that exhausted patients with CHD had
higher levels of TNF-a and IL-6 (mean rank of TNF-a
and IL-6 values of exhausted vs not exhausted were
17.9 vs 12.3, p = 0.04, and 17 vs 12, p = 0.06, respec-
tively) [10].
Even with the significant correlations reported, the
small association between systemic inflammation and
these systemic manifestations should be discussed. First,
the sample of this study composed of mainly moderate
COPD and a larger sample with a range of COPD seve-
rities would better explore this possible relationship.
S e c o n d l y ,w eh a v ec h o s e ns t a b l ep a t i e n t sa n dt h es i g n a l
may be more apparent in frequent exacerbators or
patients with major depression who are unlikely to be in
this study population. For instance, a worse scenario
would be expected had we looked at patients with less
stable patients or even patients during exacerbation,
given that others have found exacerbations are corre-
lated with systemic inflammation [34], depression [19]
and fatigue [25]. More studies, probably of longitudinal
nature will be required to disentangle these associations.
We can not preclude that our findings may be affected
by the variability in the measured biomarkers [10,35,36].
However, we measured a range of biomarkers that have
been shown to be important in studying the morbidity
and mortality in COPD [37], and we used several well-
validated subjective and objective assessment tools. We
applied strict inclusion criteria by excluding patients
with diseases that may have a potential confounding
effect. We made the effort to ensure that the blood sam-
ples were obtained carefully from clinically stable
patients. For this purpose, we excluded patients with
recent symptomatic coronary heart disease and patients
with COPD exacerbations were either rescheduled or
excluded.
Conclusion
In conclusion, our data indicate an association between
TNF-a and two major co-morbidities in COPD; i.e.,
depression and fatigue. However, further studies are
required to explore this subject and to tackle the biolo-
gical roles of these biomarkers in relation to depression
and/or fatigue.
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